Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 18:155:4243.
doi: 10.57187/s.4243.

Healthcare resource allocation for rare diseases: an exploratory survey of Swiss citizens' preferences

Federico Germani  1 , Giovanni Spitale  1 , Carola Fischer  2 , Brigitte Tag  3 , Janine Reichenbach  2   4   5 , Olivier Devuyst  6 , Matthias Baumgartner  7 , Nikola Biller-Andorno  1
Affiliations
Free article

Healthcare resource allocation for rare diseases: an exploratory survey of Swiss citizens' preferences

Federico Germani et al. Swiss Med Wkly. .
Free article

Abstract

Objective: This study explores how Swiss citizens prioritise healthcare resource allocation for rare diseases, considering variables such as disease rarity, treatment cost, patient age and treatment outcomes.

Methods: We conducted an exploratory survey using visual discrete-choice vignettes embedded in scenario cards. Each card depicted a fictional patient case based on real-world disease attributes. A total of 157 unique real-world scenarios were designed by combining variables such as rarity, age group, cost and impact on quality of life. Participants were asked whether they would recommend treatment funding for each scenario.

Results: A total of 375 participant responses were analysed. Our findings reveal that the probability of a positive decision to treat was influenced more by treatment effectiveness and quality-of-life outcomes than by disease rarity or cost.

Conclusion: The results suggest that while high treatment costs do pose challenges, they are often secondary to the perceived benefits of treatment; Swiss citizens prioritise treatment effectiveness and quality-of-life improvements over rarity or treatment cost when considering funding decisions.

PubMed Disclaimer

References

    1. 1. The Lancet Neurology. Rare neurological diseases: a united approach is needed. Lancet Neurol. 2011 Feb;10(2):109. 10.1016/S1474-4422(11)70001-1
    1. 2. Garrison S, Kennedy A, Manetto N, Pariser AR, Rutter JL, Yang G. The Economic Burden Of Rare Diseases: Quantifying The Sizeable Collective Burden And Offering Solutions. Health Aff Forefr. doi: 10.1377/forefront.20220128.987667
    1. 3. Hughes D. Rationing of drugs for rare diseases. PharmacoEconomics. 2006;24(4):315–6. 10.2165/00019053-200624040-00001
    1. 4. Kacetl J, Marešová P, Maskuriy R, Selamat A. Ethical Questions Linked to Rare Diseases and Orphan Drugs - A Systematic Review. Risk Manag Healthc Policy. 2020 Oct;13:2125–48. 10.2147/RMHP.S260641
    1. 5. Pearson C, Schapiro L, Pearson SD. The next generation of rare disease drug policy: ensuring both innovation and affordability. J Comp Eff Res. 2022 Oct;11(14):999–1010. 10.2217/cer-2022-0120